EE200200065A - 3-aminopürasooli derivaadid, nende valmistamine ja kasutamine vähivastaste toimeainetena ning neid sisaldav farmatseutiline kompositsioon - Google Patents

3-aminopürasooli derivaadid, nende valmistamine ja kasutamine vähivastaste toimeainetena ning neid sisaldav farmatseutiline kompositsioon

Info

Publication number
EE200200065A
EE200200065A EEP200200065A EEP200200065A EE200200065A EE 200200065 A EE200200065 A EE 200200065A EE P200200065 A EEP200200065 A EE P200200065A EE P200200065 A EEP200200065 A EE P200200065A EE 200200065 A EE200200065 A EE 200200065A
Authority
EE
Estonia
Prior art keywords
preparation
pharmaceutical composition
composition containing
anticancer agents
aminopyrazole derivatives
Prior art date
Application number
EEP200200065A
Other languages
English (en)
Estonian (et)
Inventor
Pevarello Paolo
Orsini Paolo
Traquandi Gabriella
Varasi Mario
L. Fritzen Edward
A. Warpehoski Martha
S. Pierce Betsy
Grabriella Brasca Maria
Original Assignee
Pharmacia Italia S.P.A.
Pharmacia & Upjohn Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia S.P.A., Pharmacia & Upjohn Company filed Critical Pharmacia Italia S.P.A.
Publication of EE200200065A publication Critical patent/EE200200065A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EEP200200065A 1999-08-12 2000-05-05 3-aminopürasooli derivaadid, nende valmistamine ja kasutamine vähivastaste toimeainetena ning neid sisaldav farmatseutiline kompositsioon EE200200065A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37283199A 1999-08-12 1999-08-12
PCT/US2000/006699 WO2001012189A1 (en) 1999-08-12 2000-05-05 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents

Publications (1)

Publication Number Publication Date
EE200200065A true EE200200065A (et) 2003-04-15

Family

ID=23469802

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200065A EE200200065A (et) 1999-08-12 2000-05-05 3-aminopürasooli derivaadid, nende valmistamine ja kasutamine vähivastaste toimeainetena ning neid sisaldav farmatseutiline kompositsioon

Country Status (35)

Country Link
US (2) US7034049B1 (is)
EP (1) EP1202733B1 (is)
JP (1) JP2003507329A (is)
KR (1) KR20020060160A (is)
CN (1) CN1373662A (is)
AP (1) AP2002002442A0 (is)
AR (1) AR026122A1 (is)
AT (1) ATE305782T1 (is)
AU (1) AU4971400A (is)
BG (1) BG106480A (is)
BR (1) BR0013143A (is)
CA (1) CA2383555C (is)
CZ (1) CZ2002422A3 (is)
DE (1) DE60023012T2 (is)
DK (1) DK1202733T3 (is)
EA (1) EA005373B1 (is)
EE (1) EE200200065A (is)
ES (1) ES2249270T3 (is)
GE (1) GEP20053476B (is)
HK (1) HK1046866A1 (is)
HR (1) HRP20020128A2 (is)
HU (1) HUP0203542A3 (is)
IL (1) IL147923A0 (is)
IS (1) IS6265A (is)
MA (1) MA25493A1 (is)
MX (1) MXPA02001498A (is)
NO (1) NO20020684L (is)
NZ (1) NZ517237A (is)
OA (1) OA12046A (is)
PE (1) PE20010130A1 (is)
PL (1) PL353455A1 (is)
SK (1) SK1812002A3 (is)
WO (1) WO2001012189A1 (is)
YU (1) YU9602A (is)
ZA (1) ZA200201511B (is)

Families Citing this family (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9901691D0 (en) 1999-01-26 1999-03-17 Cerebrus Ltd Chemical compounds
GEP20053476B (en) * 1999-08-12 2005-03-25 Upjohn Co 3(5)-Amino-Pyrazole Derivatives, Process for Their Preparation and Their Use as Antitumor Agents
EP1268472B1 (en) 2000-02-07 2004-10-13 Bristol-Myers Squibb Company 3-aminopyrazole inhibitors of cyclin dependent kinases
ES2236217T3 (es) 2000-04-25 2005-07-16 Bristol-Myers Squibb Company Uso de 5.tio.,sulfinil- y sulfonilpirazolo 3,4-b)-piridinas como inhibidores de la quinasa dependiente de la ciclina.
DE10037310A1 (de) 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
SK2002003A3 (en) * 2000-08-31 2004-04-06 Pfizer Prod Inc Pyrazole derivatives and their use as protein kinase inhibitors
US20020103185A1 (en) * 2000-08-31 2002-08-01 Sanner Mark A. Pyrazole derivatives
US20040019046A1 (en) * 2000-11-27 2004-01-29 Paolo Pevarello Phenylacetamido-pyrazole derivatives and their use as antitumor agents
US6455559B1 (en) * 2001-07-19 2002-09-24 Pharmacia Italia S.P.A. Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents
EP1379524A2 (en) * 2001-01-26 2004-01-14 Pharmacia Italia S.p.A. Chromane derivatives, process for their preparation and their use as antitumor agents
KR100589990B1 (ko) * 2001-03-02 2006-06-15 에프. 호프만-라 로슈 아게 Ｉｐ 길항제인 알콕시카보닐아미노 헤테로아릴 카복실산유도체
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
US6787555B2 (en) * 2001-04-30 2004-09-07 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
US6727364B2 (en) 2001-04-30 2004-04-27 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
EP1397137B1 (en) 2001-05-25 2009-10-14 Bristol-Myers Squibb Company Hydantion derivatives as inhibitors of matrix metalloproteinases
DE10148618B4 (de) * 2001-09-25 2007-05-03 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
DE10148617A1 (de) * 2001-09-25 2003-04-24 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
ATE440094T1 (de) * 2001-09-27 2009-09-15 Equispharm Co Ltd Fumagillolderivate und verfahren zu deren herstellung
SE0103710D0 (sv) 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
WO2003046207A2 (en) * 2001-11-27 2003-06-05 Fred Hutchinson Cancer Research Center Methods for inhibiting deacetylase activity
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
US6593477B1 (en) 2002-10-29 2003-07-15 Eastman Kodak Company Synthesis of 3-acylaminopyrazoles
EP1569929B9 (en) * 2002-12-10 2011-09-14 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of flavivirus infections
UA81790C2 (uk) 2002-12-19 2008-02-11 Фармация Италия С.П.А. Заміщені піролопіразольні похідні як інгібітори кінази
WO2004063194A1 (en) * 2003-01-06 2004-07-29 Eli Lilly And Company Heteroaryl compounds
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
CN1791402A (zh) * 2003-03-27 2006-06-21 麦克公司 治疗眼高压的眼科组合物
SE0301446D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
US7482354B2 (en) 2003-05-22 2009-01-27 Nerviano Medical Sciences S.R.L. Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
US7759382B2 (en) 2003-06-05 2010-07-20 Elan Pharmaceuticals, Inc. Acylated amino acid amidyl pyrazoles and related compounds
US7141568B2 (en) 2003-07-09 2006-11-28 Pfizer Italia S.R.L. Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
EP1670787B1 (en) 2003-09-11 2012-05-30 iTherX Pharma, Inc. Cytokine inhibitors
CA2552558A1 (en) 2004-01-16 2005-08-11 Wyeth Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole
WO2005072731A1 (en) * 2004-01-29 2005-08-11 X-Ceptor Therapeutics, Inc. 3-phenyl-n- ((1, 3, 4) thiadiazol-2-yl) -acrylamide derivatives and related compounds as modulators of estrogen-related receptors for the treatment of e.g. cancer, rheumatoid arthritis or neurological disorders
JP4960708B2 (ja) * 2004-01-30 2012-06-27 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｐ結合カセットトランスポーターのモジュレーター
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
TW200526204A (en) 2004-02-03 2005-08-16 Pharmacia Italia Spa 1h-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors
WO2005118543A1 (ja) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. キナーゼ阻害薬およびその用途
SE0401762D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
US7648992B2 (en) 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
AU2005311269B2 (en) 2004-12-03 2011-11-10 Transtech Pharma, Inc. Heteroaromatic glucokinase activators
SE0403085D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
SE0403086D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
US7361672B2 (en) 2004-12-23 2008-04-22 Hoffmann-La Roche Inc. Heteroarylacetamide inhibitors of factor Xa
FR2880540B1 (fr) * 2005-01-13 2008-07-11 Aventis Pharma Sa Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90
WO2008007113A2 (en) * 2006-07-14 2008-01-17 Astex Therapeutics Limited Pharmaceutical combinations
RU2420525C2 (ru) * 2005-07-11 2011-06-10 Мицубиси Танабе Фарма Корпорейшн Производные оксимов и их получение
US7943654B2 (en) 2005-07-19 2011-05-17 Nerviano Medical Sciences S.R.L. 1H-thieno[2,3-c]pyrazole compounds useful as kinase inhibitors
AU2006295260A1 (en) * 2005-08-29 2007-04-05 Gerard M. Housey Theramutein modulators
TW200736227A (en) 2005-12-23 2007-10-01 Astrazeneca Ab New compounds III
US20070203224A1 (en) * 2006-01-09 2007-08-30 University Of Southern California Small-molecules for treating cancer and abnormal cell proliferation disorders
WO2007095383A2 (en) * 2006-02-15 2007-08-23 Myriad Genetics, Inc. Prodrugs
UY30183A1 (es) * 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
US8211925B2 (en) 2006-04-28 2012-07-03 Transtech Pharma, Inc. Benzamide glucokinase activators
WO2007129052A1 (en) * 2006-05-03 2007-11-15 Astrazeneca Ab Pyrazole derivatives and their use as pi3k inhibitors
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
WO2008084872A1 (ja) * 2007-01-10 2008-07-17 Mitsubishi Tanabe Pharma Corporation ヒドラゾン誘導体
WO2008084873A1 (ja) * 2007-01-10 2008-07-17 Mitsubishi Tanabe Pharma Corporation オキシム誘導体
US8940900B2 (en) * 2007-02-28 2015-01-27 Advinus Therapeutics Private Limited 2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application
KR100923540B1 (ko) * 2007-11-23 2009-10-27 한국과학기술연구원 5-아실하이드라진카르보닐-3,4-디치환 피라졸 유도체 및이의 제조방법
WO2009153592A1 (en) * 2008-06-19 2009-12-23 Astrazeneca Ab Pyrazole compounds 436
US8466290B2 (en) 2008-07-10 2013-06-18 Pharma Ip General Incorporated Association STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient
WO2010009985A2 (en) 2008-07-24 2010-01-28 Nerviano Medical Sciences S.R.L. Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
NZ592801A (en) * 2008-12-05 2013-08-30 Abbvie Inc Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
MY161598A (en) * 2009-01-30 2017-04-28 Glaxosmithkline Llc Crystalline n-{ (1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl} -5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
WO2010129681A1 (en) * 2009-05-05 2010-11-11 Van Andel Research Institute Methods for treating autophagy-related disorders
BR112012003661A2 (pt) * 2009-08-19 2017-04-25 Ambit Biosciences Corp "compostos de biarila e métodos de uso dos mesmos."
IN2012DN03312A (is) 2009-10-22 2015-10-23 Fibrotech Therapeutics Pty Ltd
US20120316171A1 (en) * 2009-11-05 2012-12-13 Tamas Oravecz Tryptophan Hydroxylase Inhibitors for the Treatment of Cancer
EP2560966B1 (en) * 2010-03-30 2021-01-06 Verseon International Corporation Multisubstituted aromatic compounds as inhibitors of thrombin
SG186229A1 (en) 2010-06-07 2013-01-30 Novomedix Llc Furanyl compounds and the use thereof
EP2582666B1 (en) 2010-06-16 2014-08-13 Purdue Pharma L.P. Aryl substituted indoles and their use as blockers of sodium channels
CN105360131A (zh) * 2010-11-03 2016-03-02 陶氏益农公司 杀虫组合物和与其相关的方法
EP2651930B1 (en) * 2010-12-16 2015-10-28 Boehringer Ingelheim International GmbH Biarylamide inhibitors of leukotriene production
RU2652638C2 (ru) 2010-12-17 2018-04-28 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Замещенные пиразолхиназолиновые производные в качестве ингибиторов киназы
US20140249105A1 (en) * 2011-07-25 2014-09-04 Diverchim Novel ceramide analogues, processes for preparing same and uses thereof
AR087701A1 (es) * 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
US9056867B2 (en) * 2011-09-16 2015-06-16 Novartis Ag N-substituted heterocyclyl carboxamides
CA2852688C (en) 2011-10-26 2021-06-29 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
US9282739B2 (en) 2012-04-27 2016-03-15 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
NZ700595A (en) 2012-04-27 2016-04-29 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
US9708288B2 (en) 2012-04-27 2017-07-18 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide
CN103936637B (zh) * 2013-01-18 2016-04-06 北京大学 E-3,4-二羟苯乙烯基亚砜类化合物的制备方法及其作为神经保护药物的应用
AU2014229233B2 (en) 2013-03-15 2016-08-11 Glaxosmithkline Intellectual Property Development Limited Pyridine derivatives as rearranged during transfection (RET) kinase inhibitors
EP2970141B1 (en) 2013-03-15 2020-02-26 Verseon Corporation Halogenopyrazoles as inhibitors of thrombin
AR095308A1 (es) 2013-03-15 2015-10-07 Glaxosmithkline Ip Dev Ltd Compuesto de 2-piridona, composición farmacéutica que lo comprende y su uso para preparar un medicamento
ES2853483T3 (es) 2013-03-15 2021-09-16 Verseon Int Corporation Compuestos aromáticos multisustituidos como inhibidores de la serina proteasa
EP2996689A1 (en) 2013-04-17 2016-03-23 Albert-Ludwigs-Universität Freiburg Compounds for use as bromodomain inhibitors
CN103265535B (zh) * 2013-05-14 2015-06-17 浙江医药高等专科学校 抗肿瘤化合物、其制备方法和用途
EP3039021A1 (en) * 2013-08-30 2016-07-06 Ambit Biosciences Corporation Biaryl acetamide compounds and methods of use thereof
CN105636445B (zh) 2013-10-17 2018-12-07 美国陶氏益农公司 制备杀虫化合物的方法
CA2925873A1 (en) 2013-10-17 2015-04-23 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
CN105636442B (zh) 2013-10-17 2018-04-27 美国陶氏益农公司 制备杀虫化合物的方法
JP2016536295A (ja) 2013-10-17 2016-11-24 ダウ アグロサイエンシィズ エルエルシー 有害生物防除性化合物の製造方法
MX2016004942A (es) 2013-10-17 2016-06-28 Dow Agrosciences Llc Procesos para la preparacion de compuestos plaguicidas.
KR20160074540A (ko) 2013-10-17 2016-06-28 다우 아그로사이언시즈 엘엘씨 살충성 화합물의 제조 방법
CA2925952A1 (en) 2013-10-17 2015-04-23 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
WO2015061165A1 (en) 2013-10-22 2015-04-30 Dow Agrosciences Llc Pesticidal compositions and related methods
NZ719776A (en) 2013-10-22 2017-06-30 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
CA2927220A1 (en) 2013-10-22 2015-04-30 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
KR102275655B1 (ko) 2013-10-22 2021-07-09 코르테바 애그리사이언스 엘엘씨 살충 조성물 및 관련 방법
JP2016534076A (ja) 2013-10-22 2016-11-04 ダウ アグロサイエンシィズ エルエルシー 相乗的有害生物防除組成物および関連する方法
CA2926433A1 (en) 2013-10-22 2015-04-30 Dow Agrosciences Llc Pesticidal compositions and related methods
US9549560B2 (en) 2013-10-22 2017-01-24 Dow Agrosciences Llc Pesticidal compositions and related methods
WO2015061148A1 (en) 2013-10-22 2015-04-30 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
AR098091A1 (es) 2013-10-22 2016-05-04 Dow Agrosciences Llc Composiciones pesticidas sinérgicas y métodos relacionados
CN105828612A (zh) 2013-10-22 2016-08-03 美国陶氏益农公司 协同杀虫组合物和相关方法
KR102286233B1 (ko) 2013-10-22 2021-08-06 코르테바 애그리사이언스 엘엘씨 살충 조성물 및 관련 방법
WO2015061163A1 (en) 2013-10-22 2015-04-30 Dow Agrosciences Llc Pesticidal compositions and related methods
MX2016005310A (es) 2013-10-22 2016-08-08 Dow Agrosciences Llc Composiciones pesticidas sinergicas y metodos relacionados.
AU2014340416B2 (en) 2013-10-22 2017-09-07 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
AR098097A1 (es) 2013-10-22 2016-05-04 Dow Agrosciences Llc Composiciones plaguicidas sinérgicas y métodos relacionados
WO2015061146A1 (en) 2013-10-22 2015-04-30 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
CA2926345A1 (en) 2013-10-22 2015-04-30 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
WO2015143653A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
AR098108A1 (es) 2014-07-31 2016-05-04 Dow Agrosciences Llc Proceso para la preparación de 3-(3-cloro-1h-pirazol-1-il)piridina
JP2017523163A (ja) 2014-07-31 2017-08-17 ダウ アグロサイエンシィズ エルエルシー ３−（３−クロロ−１ｈ−ピラゾール−１−イル）ピリジンの製造方法
EP3186229A4 (en) 2014-07-31 2018-01-10 Dow AgroSciences LLC Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
CN107074774A (zh) 2014-08-19 2017-08-18 美国陶氏益农公司 制备3‑(3‑氯‑1h‑吡唑‑1‑基)吡啶的方法
MX381233B (es) 2014-09-10 2025-03-12 Glaxosmithkline Ip Dev Ltd Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret).
RS58813B1 (sr) 2014-09-10 2019-07-31 Glaxosmithkline Ip Dev Ltd Piridonski derivati korišćeni kao inhibitori kinaze reorganizovane tokom transfekcije (ret)
WO2016039781A1 (en) 2014-09-12 2016-03-17 Dow Agrosciences Llc Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
BR112017004704A2 (pt) 2014-09-17 2018-01-23 Verseon Corp composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio em um indivíduo
GB201416513D0 (en) * 2014-09-18 2014-11-05 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
US10532995B2 (en) 2015-02-27 2020-01-14 Verseon Corporation Substituted pyrazole compounds as serine protease inhibitors
CA2978170C (en) 2015-03-09 2024-02-27 Aurigene Discovery Technologies Limited Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
KR20180017013A (ko) 2015-05-06 2018-02-20 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 K-Ras 조절제
EP3302448B1 (en) 2015-06-04 2023-10-25 Aurigene Oncology Limited Substituted heterocyclyl derivatives as cdk inhibitors
CA3032586A1 (en) 2016-08-12 2018-02-15 Athenex, Inc. Biaryl compounds and use thereof for modulating a kinase cascade
KR20190098204A (ko) * 2016-12-29 2019-08-21 엔요 파마 항바이러스제로서의 티오펜 유도체
CN110325036B (zh) 2016-12-29 2021-10-26 美国陶氏益农公司 用于制备杀虫化合物的方法
CN110139853B (zh) 2016-12-29 2023-06-16 美国陶氏益农公司 用于制备杀有害生物化合物的方法
EP3577103A1 (en) 2017-02-03 2019-12-11 Certa Therapeutics Pty Ltd. Anti-fibrotic compounds
MA49014A (fr) 2017-03-21 2020-02-05 Arbutus Biopharma Corp Dihydroindène-4-carboxamides substitués, leurs analogues et procédés d'utilisation correspondant
CN110785414A (zh) 2017-04-20 2020-02-11 加利福尼亚大学董事会 K-Ras调节剂
EP3720436A4 (en) 2017-12-06 2021-06-02 Lin Bioscience, Pty Ltd. TUBULIN INHIBITORS
CN111741944B (zh) * 2018-02-01 2025-01-03 悉尼大学 抗癌化合物
WO2019193509A1 (en) * 2018-04-04 2019-10-10 Aurigene Discovery Technologies Limited Substituted pyrazole derivatives as selective cdk12/13 inhibitors
EP3906029A4 (en) 2018-12-31 2022-09-21 Biomea Fusion, LLC INHIBITORS OF MENIN-MLL INTERACTION
EA202191852A1 (ru) 2018-12-31 2022-03-18 Биомеа Фьюжн, Ллс Необратимые ингибиторы взаимодействия менин-mll
CA3166455A1 (en) * 2020-01-29 2021-08-05 Neville John ANTHONY Heterocyclic compounds useful for modulating baf complexes
CN111793034B (zh) * 2020-07-24 2021-11-19 华中科技大学 苯并咪唑盐衍生物与制备抗肿瘤药物的应用
AU2021359129A1 (en) * 2020-10-16 2023-06-01 Proxygen Gmbh Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
TW202229268A (zh) * 2020-12-22 2022-08-01 大陸商上海拓界生物醫藥科技有限公司 Ｃｄｋ２抑制劑及其製備方法
AU2022325861A1 (en) 2021-08-11 2024-02-29 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
IL310717A (en) 2021-08-20 2024-04-01 Biomea Fusion Inc Crystalline form of N-[4-[4-(4-morpholinyl)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO ] -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, IRREVERSIBLE MENIN-MLL INHIBITOR FOR CANCER TREATMENT
WO2023107714A2 (en) * 2021-12-10 2023-06-15 Prothena Biosciences Limited Methods for treating neurological disorders
WO2023203172A1 (en) * 2022-04-20 2023-10-26 Proxygen Gmbh Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
TW202430528A (zh) 2023-01-18 2024-08-01 美商拜歐米富士恩股份有限公司 Ｎ－［４－［４－（４－嗎啉基）－７ｈ－吡咯並［２，３－ｄ］嘧啶－６－基］苯基］－４－［［３（ｒ）－［（１－氧代－２－丙烯－１－基）氨基］－１－哌啶基］甲基］－２－吡啶甲醯胺的結晶形式作為ｍｅｎｉｎ－ｍｌｌ相互作用的共價抑制劑
CN116496151B (zh) * 2023-04-26 2024-08-23 长沙医学院 一种利用Catellani策略制备芴酮衍生物的方法
CN118221668A (zh) * 2024-03-19 2024-06-21 华南农业大学 一种含2-氨基-1,3,4-噻二唑的吲哚美辛衍生物及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162360A (en) 1991-06-24 1992-11-10 Warner-Lambert Company 2-heteroatom containing urea and thiourea ACAT inhibitors
KR970706813A (ko) 1994-11-10 1997-12-01 찰스 홈시 단백질 키나아제의 억제물질로서 유용한 제약용 피라졸 조성물(pharmaceutical pyrazole compositions useful as inhibitors of protein kinases)
AU5135998A (en) 1996-12-03 1998-06-29 Banyu Pharmaceutical Co., Ltd. Novel urea derivatives
AU7726898A (en) 1997-05-22 1998-12-11 G.D. Searle & Co. Pyrazole derivatives as p38 kinase inhibitors
ES2154253T3 (es) 1997-12-22 2012-01-27 Bayer Healthcare Llc Inhibición de la actividad de p38 cinasa usando ureas heterocíclicas sustituidas.
DE69834842T2 (de) 1997-12-22 2007-05-10 Bayer Pharmaceuticals Corp., West Haven Hemmung von raf-kinase unter verwendung von aryl- und heteroarylsubstituierten heterocyclischen harnstoffen
GEP20053476B (en) * 1999-08-12 2005-03-25 Upjohn Co 3(5)-Amino-Pyrazole Derivatives, Process for Their Preparation and Their Use as Antitumor Agents
US6455559B1 (en) * 2001-07-19 2002-09-24 Pharmacia Italia S.P.A. Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents

Also Published As

Publication number Publication date
NZ517237A (en) 2004-02-27
PE20010130A1 (es) 2001-02-01
ES2249270T3 (es) 2006-04-01
GEP20053476B (en) 2005-03-25
AR026122A1 (es) 2003-01-29
EA005373B1 (ru) 2005-02-24
BR0013143A (pt) 2002-06-11
SK1812002A3 (en) 2003-02-04
US7034049B1 (en) 2006-04-25
YU9602A (sh) 2004-11-25
OA12046A (en) 2006-05-02
EP1202733A1 (en) 2002-05-08
CA2383555A1 (en) 2001-02-22
KR20020060160A (ko) 2002-07-16
MXPA02001498A (es) 2003-07-21
US6218418B1 (en) 2001-04-17
HUP0203542A2 (en) 2003-05-28
MA25493A1 (fr) 2002-07-01
PL353455A1 (en) 2003-11-17
BG106480A (en) 2002-09-30
EP1202733B1 (en) 2005-10-05
HRP20020128A2 (en) 2003-04-30
WO2001012189A1 (en) 2001-02-22
HK1046866A1 (zh) 2003-01-30
IS6265A (is) 2002-02-11
NO20020684L (no) 2002-04-03
IL147923A0 (en) 2002-08-14
EP1202733A4 (en) 2003-05-14
DE60023012T2 (de) 2006-07-20
NO20020684D0 (no) 2002-02-11
CZ2002422A3 (cs) 2002-11-13
DK1202733T3 (da) 2005-10-31
ATE305782T1 (de) 2005-10-15
JP2003507329A (ja) 2003-02-25
AP2002002442A0 (en) 2002-03-31
DE60023012D1 (de) 2006-02-16
WO2001012189A8 (en) 2001-08-02
HUP0203542A3 (en) 2003-07-28
CA2383555C (en) 2009-02-17
CN1373662A (zh) 2002-10-09
EA200200248A1 (ru) 2002-08-29
AU4971400A (en) 2001-03-13
ZA200201511B (en) 2003-05-28

Similar Documents

Publication Publication Date Title
EE200200065A (et) 3-aminopürasooli derivaadid, nende valmistamine ja kasutamine vähivastaste toimeainetena ning neid sisaldav farmatseutiline kompositsioon
EE200300046A (et) Asabitsüklilised ühendid, nende valmistamine ja kasutamine ravimitena ning neid sisaldav farmatseutiline kompositsioon
EE04673B1 (et) Kinoliini derivaadid, nende valmistamine ja kasutamine ravimina ning neid sisaldavad farmatseutilised kompositsioonid
EE200200064A (et) Arüülmetüülkarbonüülaminotiasooli derivaadid, nende valmistamine ja kasutamine vähivastaste toimeainetena
EE200200138A (et) Kinolüülpropüülpiperidiini derivaadid, nende valmistamine ja neid sisaldavad kompositsioonid
EE200300080A (et) Polüarüülkarboksamiidühendid, nende valmistamine ja kasutamine lipiiditaset alandavate toimeainetena ning neid sisaldav farmatseutiline kompositsioon
EE200000168A (et) Karboksamidotiasoolderivaadid, nende valmistamine ja neid sisaldavad farmatseutilised kompositsioonid
EE04679B1 (et) Tuumorivastase toimega kamptotetsiini derivaadid,meetod nende valmistamiseks ja neid hendeid sisaldavad farmatseutilised kompositsioonid
EE04276B1 (et) Kinoliini derivaadid, nende valmistamine ja kasutamine ravimina ning neid sisaldavad farmatseutilised kompositsioonid
EE05181B1 (et) Prasolo[4,3-d]primidiini derivaadid, neid sisaldavad farmatseutilised kompositsioonid, nende kasutamine ja meetodid nende valmistamiseks
EE200100399A (et) Pürasoolkarboksüülhappe derivaadid, nende valmistamine ja neid sisaldavad farmatseutilised kompositsioonid
HUP0204143A3 (en) Tricyclic 1-benzylpyrazole-3-carboxylic acid derivatives, preparation of the compounds, their use and pharmaceutical compositions containing them
EE04282B1 (et) Pürasoolpürimidiinid, nende valmistamine ja kasutamine ravimina ning neid sisaldav kompositsioon
EE04399B1 (et) Spiroasabitsüklilised heterotsüklilised ühendid, nende valmistamise protsess, neid sisaldavad ravimkoostised ja nende kasutamine ravis
EE05034B1 (et) Bitsüklilised heterotsüklilised ühendid, neid ühendeid sisaldavad farmatseutilised kompositsioonid ja nende valmistamise meetodid
EE200100446A (et) Uued tritsüklilised ühendid ja nende kasutamine meditsiinis: nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid
EE05001B1 (et) Heterotsüklilised ühendid, meetod nende valmistamiseks, neid sisaldav ravimkoostis ning nende kasutamine ravis
EE04965B1 (et) Imidasoimidasoolid ja triasoolid kui p?letikuvastased hendid, nende kasutamine ravimite valmistamiseks ning farmatseutiline kompositsioon
EE200200409A (et) 1,3-dihüdro-2H-indool-2-ooni derivaadid, nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid
EE200100684A (et) Indalüülasendatud benseenkarboksamiidid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
EE05149B1 (et) Biarlkarboksamiidid, meetod nende valmistamiseks, neid sisaldav ravimkoostis ning nende kasutamine ravis
HUP0203509A3 (en) Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same
EE200100252A (et) Pürimidiinderivaadid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja sellevalmistamismeetod, kombinatsioon ning saadus
IL148876A0 (en) Sulfonamide derivatives, their preparation and pharmaceutical compositions containing them
IL146545A0 (en) Benzene derivatives, preparation method and pharmaceutical compositions containing same